The Effectiveness of Transcranial Direct Current Stimulation as Adjunctive Treatment for Chronic Daily Headache in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus Clinical Trial

— SHADE  

Official title:

The Effectiveness of Transcranial Direct Current Stimulation (tDCS) as Adjunctive Treatment for Chronic Daily Headache in Systemic Lupus Erythematosus: A Double Blind Randomized Multi-Arm Sham Controlled Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05613582
• Other study ID #: 22070753
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 20, 2022
• Est. completion date: September 20, 2023

Study information

• Verified date: November 2022
• Source: Indonesia University
• Contact: Dyah Tunjungsari, MD
• Phone: +628119884224
• Email: penelitian.neuroui[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The prevalence of chronic primary headache in Systemic Lupus Erythematosus (SLE) is 54.4%. Several studies have shown that the use of transcranial direct current stimulation (tDCS) at the primary motor cortex (M1), primary sensory cortex (S1), or dorsolateral prefrontal cortex (DLPFC) is effective as adjuvant therapy in primary headache. Using a double-blind design, this clinical trial study will investigate the effectiveness of tDCS as an adjuvant therapy in chronic daily headaches in SLE, by also comparing the effectiveness of administration in the M1, S1, and DLPFC. The primary endpoint that will be assessed is the frequency of headaches per week, with the secondary endpoints are the degree of headache, quality of life, sleep quality, level of depression, and use of analgesics.

Description:

This study aimed to assess the effectiveness of the tDCS protocol as an adjuvant therapy for reducing chronic headache in SLE. It is also hoped that this study will obtain an effective tDCS protocol for chronic headache. The whole procedure will run for 20 weeks, divided into 3 parts (Pre-intervention, Intervention, and Post-intervention) Pre-intervention (weeks 0-4) to conduct screening, provide informed consent, and also baseline assessment. Participants will come in weeks 0 and 4. Intervention (weeks 4-8) to perform the TDCS intervention, record and assess outcomes, and assess if an unwanted event occurs. Participants will come 2 times per week, from week 4 to 8 Post-intervention (weeks 8-20) for continued outcome assessment. Participants will come on weeks 8, 12, 16, and 20 The total number of visits from each participant is 14 times SLE patients who meet the inclusion criteria and have signed the consent will be subjected to a baseline assessment (weeks 0-4) followed by randomization into 4 groups/arms consisting of 3 treatments (getting standard therapy for SLE and other diseases that have been obtained so far, plus the administration of tDCS at DLPC, M1, S1) and 1 control group that got sham tDCS. If the tDCS intervention shows effective and safe results, then the subject in the control group (the group that received the sham) will be offered to be given the intervention method at the end of the study. Any unwanted event (adverse event) that occurs will be recorded. If an undesirable event occurs, a written report will be made to the ethics committee. Demographic data will be presented descriptively according to the type of data. Normality test will be performed with Shapiro-Wilkins. To find out the changes in the frequency of headaches in the four groups, an analysis using one-way Anova was carried out followed by Bonferroni post hoc analysis with a significance level of 0.05. The effect size of each group will also be analyzed with Cohen's d=02 (small effect), 0.5 (medium) and 0.8 (large) parameters. Data analysis will be carried out using SPSS 23.0 and GraphPad software.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 88
• Est. completion date: September 20, 2023
• Est. primary completion date: July 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age > 18 years old

2. Patients who have been diagnosed with SLE based on the 2019 ACR criteria

3. Meet the criteria for the diagnosis of chronic headache (criteria based on the International Headache Society, headache occurs in 15 days or more per month, occurs for at least 3 months)

Exclusion Criteria:

1. The patient or the patient's family refuses to participate in the study

2. Is in a state of relapse/flare

3. Allergic reactions / skin infections / wounds / cranial defects / metal implants in the electrode installation area

4. Have a history of brain tumor, severe head injury, stroke

Related Conditions & MeSH terms

• Chronic Headache
• Headache
• Headache Disorders
• Lupus Erythematosus, Systemic
• Systemic Lupus Erythematosus

Intervention

Device:
• Transcranial Direct Current Stimulation
The flow of DC electric current 1 mA for 20 minutes. The position of the electrode placement follows the international EEG 10/20 system.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Indonesia University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Headache Frequency	Headache Frequency will be assessed using the headache diary, with a reduced number of frequencies, it indicates a better output	Change from baseline, at the end of weeks 8, and during the follow up period (end of weeks 12, 16, and 20)
Secondary	Headache Assessed by Visual Analouge Scale	Minimum value: 0 cm Maximum value: 10 cm Assessment using a straight line 10 cm long. Both ends showed signs at 0 cm not painful and the other end at 10 cm very painful. The patient then marks along the line that interprets the pain.	Change from baseline, 4th, 5th-8th, 12th, 16th, 20th week
Secondary	Functional Aspects of Headache-Related Quality of Life Assessed by Chronic Headache Quality of Life Questionnaire (CHQLQ)	Lowest score 0 Highest score 300 The higher the value, the worse the outcome	4th, 8th, 12th, 16th, 20th week
Secondary	Health-Related Quality of Life Assessed by The 36-Item Short Form Health Survey Questionnaire (SF-36)	Lowest score: 0 Highest score: 100 Higher scores indicate better health status, and a mean score of 50 has been articulated as a normative value for all scales	4th, 8th, 12th, 16th, 20th week
Secondary	Sleep Quality Assessed by Pittsburgh Sleep Quality Index (PSQI)	Lowest score: 0 Highest score: 21 The higher the value, the worse the outcome	4th, 8th, 12th, 16th, 20th week
Secondary	Depression level assessed by Mini International Neuropsychiatric Interview Version ICD-10 (MINI ICD 10)	Will be assessed whether the subject has a depressive episode (Yes/No)	4th, 8th, 12th, 16th, 20th week
Secondary	Frequency of use of analgesics	Assessment using records of frequency of analgesic consumption	Change from baseline until week 8th, followed at 12th, 16th, 20th week
Secondary	Amount of analgesic use	Assessment using records of frequency of amount of analgesic use	Change from baseline until week 8th, followed at 12th, 16th, 20th week